Major Health Insurers See Stock Surge After Medicare Approves 2027 Payment Increase
New York, Monday, 6 April 2026.
A finalized 2.48% Medicare rate increase for 2027 will inject over $13 billion into the sector, prompting a massive market rally led by a 12% surge in Humana shares.
Wall Street Responds to Favorable Rate Adjustments
On Monday, April 6, 2026, the Centers for Medicare and Medicaid Services (CMS) finalized a 2.48 percent payment rate increase for private Medicare Advantage insurers for the 2027 contract year [1]. This finalized rate marks a significant improvement over the initial proposals released in January, injecting a projected $13 billion in additional Medicare Advantage payments into the sector [1]. Following the after-hours announcement, Humana shares jumped 12 percent, while UnitedHealth Group and CVS Health gained 11 percent and 9 percent, respectively [1]. Elevance Health also climbed 5 percent, and hospital equities advanced, with some shares rising between 4 percent and 7 percent [1].
Methodological Shifts in Risk Adjustment
Beyond the headline rate increase, the 2027 Rate Announcement introduces critical operational changes to how insurers calculate patient risk. CMS confirmed it will continue using the 2024 Medicare Advantage risk adjustment model for 2027, having evaluated the model’s impact between 2024 and 2026 [1].
Broader Part D Redesign and Cost-Sharing Limits
The rate boost coincides with a massive final rule published in the Federal Register on April 6, 2026, which amends regulations across the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) programs [2]. The rule, which garnered exactly 42,632 pieces of correspondence during its public comment period, codifies structural changes initiated by the Inflation Reduction Act of 2022 (IRA) [2].
Manufacturer Discounts and Specialty Tier Caps
The regulatory framework also finalizes the transition away from the Coverage Gap Discount Program, which sunsetted on January 1, 2025, replacing it entirely with the Manufacturer Discount Program [2]. Under this new program, applicable discounts of 10 percent or 20 percent on negotiated drug prices are available in the initial and catastrophic coverage phases, respectively, once a beneficiary exceeds the annual deductible [2].